Novartis is gaining in emerging markets. It's also seeing growth in newly launched products, including a few potential blockbusters. Both very good things--and sorely needed to offset a manufacturing shutdown and eroding sales of its top-selling drug.
Novartis CEO Joe Jimenez managed to impress the Wall Street crowd today with some solid numbers for the second quarter.
For the second quarter in a row, Johnson & Johnson posted a downward tick in revenues, hobbled by currency losses. Asset writedowns, legal-settlement set-asides, and acquisition costs dug into earnings.
AstraZeneca doesn't shy from a challenge. The drugmaker ($AZN) has launched a study comparing its clot-fighter Brilinta with the standard bloodthinner treatment Plavix, in patients with peripheral artery disease.
A federal appeals court pulled a pay-to-delay challenge out of mothballs, forcing Merck to fight claims that its Schering-Plough unit delayed generic versions of its potassium drug K-Dur. But Merck isn't the only drugmaker that should keep an eye on this case.
Analysts have put a pencil to the Par Pharmaceutical buyout, and they've concluded the company could bring a good bit more than $50 per share from a generics-industry bidder.
After unsuccessfully struggling for three months to spur a bidding war, Human Genome Sciences appears ready to throw in the towel today and accept a slightly sweetened offer from longtime partner GlaxoSmithKline.
Ipsen's news isn't all bad these days. After its big plans for a new hemophilia drug hit a big snag earlier this week, the drugmaker is announcing plans to keep a French plant it had slated for sale.
Eli Lilly can enjoy competition-free Cymbalta sales for 6 months longer.
Stock analysts have called for Forest Laboratories to jump on the M&A bandwagon in biopharma as the drugmaker's top-selling Lexapro faces generic drug competition.